Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- association label "carbidopa tablets are indicated for use with carbidopa levodopa or with levodopa in the treatment of the symptoms of idiopathic parkinson s disease paralysis agitans postencephalitic parkinsonism and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and or manganese intoxication carbidopa is for use with carbidopa levodopa in patients for whom the dosage of carbidopa levodopa provides less than adequate daily dosage usually 7 mg daily of carbidopa carbidopa is for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each medication carbidopa is used with carbidopa levodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting more rapid dosage titration and with a somewhat smoother response however patients with markedly irregular on off responses to levodopa have not been shown to benefit from the addition of carbidopa since carbidopa prevents the reversal of levodopa effects caused by pyridoxine supplemental pyridoxine vitamin b6 can be given to patients when they are receiving carbidopa and levodopa concomitantly or as carbidopa levodopa although the administration of carbidopa permits control of parkinsonism and parkinson s disease with much lower doses of levodopa there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting permitting more rapid titration and providing a somewhat smoother response to levodopa certain patients who responded poorly to levodopa alone have improved when carbidopa and levodopa were given concurrently this was most likely due to decreased peripheral decarboxylation of levodopa rather than to a primary effect of carbidopa on the peripheral nervous system carbidopa has not been shown to enhance the intrinsic efficacy of levodopa in deciding whether to give carbidopa with carbidopa levodopa or with levodopa to patients who have nausea and or vomiting the physician should be aware that while many patients may be expected to improve some may not since one cannot predict which patients are likely to improve this can only be determined by a trial of therapy it should be further noted that in controlled trials comparing carbidopa and levodopa with levodopa alone about half the patients with nausea and or vomiting on levodopa alone improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial" assertion.
- association label "erivedge is indicated for the treatment of adults with metastatic basal cell carcinoma or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation erivedge r 1" assertion.
- association label "sirturo is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adults 18 years and older with pulmonary multi drug resistant tuberculosis mdr tb reserve sirturo for use when an effective treatment regimen cannot otherwise be provided administer sirturo by directly observed therapy dot this indication is approved under accelerated approval based on time to sputum culture conversion see clinical studies 14 sirturo is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adults 18 years and older with pulmonary multi drug resistant tuberculosis mdr tb reserve sirturo for use when an effective treatment regimen cannot otherwise be provided administer sirturo by directly observed therapy dot 1 2 1 this indication is approved under accelerated approval based on time to sputum culture conversion continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials 1 14 limitations of use 1 14 limitations of use do not use sirturo for the treatment of latent infection due to mycobacterium tuberculosis drug sensitive tuberculosis extra pulmonary tuberculosis infections caused by non tuberculous mycobacteria the safety and efficacy of sirturo in the treatment of hiv infected patients with mdr tb have not been established as clinical data are limited see clinical studies 14" assertion.
- association label "luzu luliconazole cream 1 is indicated for the topical treatment of interdigital tinea pedis tinea cruris and tinea corporis caused by the organisms trichophyton rubrum epidermophyton floccosum luzu luliconazole cream 1 is an azole antifungal indicated for the topical treatment of interdigital tinea pedis tinea cruris and tinea corporis caused by the organisms trichophyton rubrum epidermophyton floccosum 1" assertion.
- association label "incruse ellipta is indicated for the long term once daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease copd including chronic bronchitis and or emphysema incruse ellipta is an anticholinergic indicated for the long term once daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease copd 1" assertion.
- association label "rapivab is an influenza virus neuraminidase inhibitor indicated for the treatment of acute uncomplicated influenza in patients 2 years and older who have been symptomatic for no more than two days 1 limitations of use efficacy based on clinical trials in which the predominant influenza virus type was influenza a a limited number of subjects infected with influenza b virus were enrolled 1 consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use 1 efficacy could not be established in patients with serious influenza requiring hospitalization 1 limitations of use efficacy of rapivab is based on clinical trials of naturally occurring influenza in which the predominant influenza infections were influenza a virus a limited number of subjects infected with influenza b virus were enrolled influenza viruses change over time emergence of resistance substitutions could decrease drug effectiveness other factors for example changes in viral virulence might also diminish clinical benefit of antiviral drugs prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use rapivab see microbiology 12 4 the efficacy of rapivab could not be established in patients with serious influenza requiring hospitalization see clinical studies 14 3" assertion.
- association label "savaysa is a factor xa inhibitor indicated to reduce the risk of stroke and systemic embolism se in patients with nonvalvular atrial fibrillation nvaf 1 1 limitation of use for nvaf savaysa should not be used in patients with creatinine clearance crcl 95 ml min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied 6 mg 1 1 savaysa is indicated for the treatment of deep vein thrombosis dvt and pulmonary embolism pe following 5 to 1 days of initial therapy with a parenteral anticoagulant 1 2 savaysa is indicated to reduce the risk of stroke and systemic embolism se in patients with nonvalvular atrial fibrillation nvaf limitation of use for nvaf savaysa should not be used in patients with crcl 95 ml min because of an increased risk of ischemic stroke compared to warfarin see dosage and administr ation 2 1 warnings and precautions 5 1 clinical studies 14 1 savaysa is indicated for the treatment of deep vein thrombosis dvt and pulmonary embolism pe following 5 to 1 days of initial therapy with a parenteral anticoagulant" assertion.
- association label "acthar gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age 1 1 acthar gel is indicated for the treatment of exacerbations of multiple sclerosis in adults 1 2 acthar gel may be used for the following disorders and diseases rheumatic collagen dermatologic allergic states ophthalmic respiratory and edematous state 1 3 1 9 acthar gel repository corticotropin injection is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age acthar gel repository corticotropin injection is indicated for the treatment of acute exacerbations of multiple sclerosis in adults controlled clinical trials have shown acthar gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis however there is no evidence that it affects the ultimate outcome or natural history of the disease as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require low dose maintenance therapy ankylosing spondylitis during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus systemic dermatomyositis polymyositis severe erythema multiforme stevens johnson syndrome serum sickness severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as keratitis iritis iridocyclitis diffuse posterior uveitis and choroiditis optic neuritis chorioretinitis anterior segment inflammation symptomatic sarcoidosis to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus" assertion.
- association label "natpara is a parathyroid hormone indicated as an adjunct to calcium and vitamin d to control hypocalcemia in patients with hypoparathyroidism limitations of use because of the potential risk of osteosarcoma natpara is recommended only for patients who cannot be well controlled on calcium supplements and active forms of vitamin d alone see warnings and precautions 5 1 natpara was not studied in patients with hypoparathyroidism caused by calcium sensing receptor mutations natpara was not studied in patients with acute post surgical hypoparathyroidism natpara is a parathyroid hormone indicated as an adjunct to calcium and vitamin d to control hypocalcemia in patients with hypoparathyroidism 1 limitations of use because of the potential risk of osteosarcoma natpara is recommended only for patients who cannot be well controlled on calcium supplements and active forms of vitamin d alone 5 1 natpara was not studied in patients with hypoparathyroidism caused by calcium sensing receptor mutations natpara was not studied in patients with acute post surgical hypoparathyroidism" assertion.
- association label "alecensa is indicated for the treatment of patients with anaplastic lymphoma kinase alk positive metastatic non small cell lung cancer nsclc as detected by an fda approved test alecensa is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase alk positive metastatic non small cell lung cancer nsclc as detected by an fda approved test 1" assertion.
- association label "unituxin dinutuximab is indicated in combination with granulocyte macrophage colony stimulating factor gm csf interleukin 2 il 2 and 13 cis retinoic acid ra for the treatment of pediatric patients with high risk neuroblastoma who achieve at least a partial response to prior first line multiagent multimodality therapy see clinical studies 14 unituxin is a gd2 binding monoclonal antibody indicated in combination with granulocyte macrophage colony stimulating factor gm csf interleukin 2 il 2 and 13 cis retinoic acid ra for the treatment of pediatric patients with high risk neuroblastoma who achieve at least a partial response to prior first line multiagent multimodality therapy 1" assertion.
- association label "afinitor is a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptor positive her2 negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole 1 1 adults with progressive neuroendocrine tumors of pancreatic origin pnet and adults with progressive well differentiated non functional neuroendocrine tumors net of gastrointestinal gi or lung origin that are unresectable locally advanced or metastatic limitation of use 1 2 adults with advanced renal cell carcinoma rcc after failure of treatment with sunitinib or sorafenib 1 3 adults with renal angiomyolipoma and tuberous sclerosis complex tsc not requiring immediate surgery 1 4 afinitor and afinitor disperz are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with tsc who have subependymal giant cell astrocytoma sega that requires therapeutic intervention but cannot be curatively resected 1 5 afinitor disperz is a kinase inhibitor indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tsc associated partial onset seizures 1 6 afinitor r afinitor is indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin pnet with unresectable locally advanced or metastatic disease afinitor is indicated for the treatment of adult patients with progressive well differentiated non functional net of gastrointestinal gi or lung origin with unresectable locally advanced or metastatic disease limitation of use see clinical studies 14 2 afinitor is indicated for the treatment of adult patients with advanced rcc after failure of treatment with sunitinib or sorafenib afinitor is indicated for the treatment of adult patients with renal angiomyolipoma and tsc not requiring immediate surgery afinitor and afinitor disperz r afinitor disperz is indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tsc associated partial onset seizures" assertion.
- association label "prolia is a rank ligand rankl inhibitor indicated for treatment of postmenopausal women with osteoporosis at high risk for fracture 1 1 treatment to increase bone mass in men with osteoporosis at high risk for fracture 1 2 treatment of glucocorticoid induced osteoporosis in men and women at high risk for fracture 1 3 treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer 1 4 treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer 1 5 prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture or multiple risk factors for fracture or patients who have failed or are intolerant to other available osteoporosis therapy in postmenopausal women with osteoporosis prolia reduces the incidence of vertebral nonvertebral and hip fractures see clinical studies 14 1 prolia is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture or multiple risk factors for fracture or patients who have failed or are intolerant to other available osteoporosis therapy see clinical studies 14 2 prolia is indicated for the treatment of glucocorticoid induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7 5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months high risk of fracture is defined as a history of osteoporotic fracture multiple risk factors for fracture or patients who have failed or are intolerant to other available osteoporosis therapy see clinical studies 14 3 prolia is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer in these patients prolia also reduced the incidence of vertebral fractures see clinical studies 14 4 prolia is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer see clinical studies 14 5" assertion.
- association label "stelara r adult patients with moderate to severe plaque psoriasis ps 1 1 active psoriatic arthritis psa 1 2 moderately to severely active crohn s disease cd failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed a tumor necrosis factor tnf blocker or failed or were intolerant to treatment with one or more tnf blockers 1 3 adolescent patients 12 years or older with moderate to severe plaque psoriasis 1 1 stelara r stelara r r stelara r failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with a tumor necrosis factor tnf blocker or failed or were intolerant to treatment with one or more tnf blockers" assertion.
- association label "simponi is a tumor necrosis factor tnf blocker indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis ra in combination with methotrexate 1 1 active psoriatic arthritis psa alone or in combination with methotrexate 1 2 active ankylosing spondylitis as 1 3 moderate to severe ulcerative colitis uc with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy 1 4 inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders simponi in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis simponi alone or in combination with methotrexate is indicated for the treatment of adult patients with active psoriatic arthritis simponi is indicated for the treatment of adult patients with active ankylosing spondylitis simponi is indicated in adult patients with moderately to severely active ulcerative colitis who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates oral corticosteroids azathioprine or 6 mercaptopurine for inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders see clinical studies 14 4" assertion.
- association label "cimzia is a tumor necrosis factor tnf blocker indicated for reducing signs and symptoms of crohn s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 1 treatment of adults with moderately to severely active rheumatoid arthritis 1 2 treatment of adult patients with active psoriatic arthritis 1 3 treatment of adults with active ankylosing spondylitis 1 4 treatment of adults with active non radiographic axial spondyloarthritis with objective signs of inflammation 1 5 treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy 1 6 cimzia is indicated for reducing signs and symptoms of crohn s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy cimzia is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis ra cimzia is indicated for the treatment of adult patients with active psoriatic arthritis psa cimzia is indicated for the treatment of adults with active ankylosing spondylitis as see clinical studies 14 4 cimzia is indicated for the treatment of adults with active non radiographic axial spondyloarthritis nr axspa with objective signs of inflammation see clinical studies 14 5 cimzia is indicated for the treatment of adults with moderate to severe plaque psoriasis pso who are candidates for systemic therapy or phototherapy see clinical studies 14 6" assertion.
- association label "cimzia is a tumor necrosis factor tnf blocker indicated for reducing signs and symptoms of crohn s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 1 treatment of adults with moderately to severely active rheumatoid arthritis 1 2 treatment of adult patients with active psoriatic arthritis 1 3 treatment of adults with active ankylosing spondylitis 1 4 treatment of adults with active non radiographic axial spondyloarthritis with objective signs of inflammation 1 5 treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy 1 6 cimzia is indicated for reducing signs and symptoms of crohn s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy cimzia is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis ra cimzia is indicated for the treatment of adult patients with active psoriatic arthritis psa cimzia is indicated for the treatment of adults with active ankylosing spondylitis as see clinical studies 14 4 cimzia is indicated for the treatment of adults with active non radiographic axial spondyloarthritis nr axspa with objective signs of inflammation see clinical studies 14 5 cimzia is indicated for the treatment of adults with moderate to severe plaque psoriasis pso who are candidates for systemic therapy or phototherapy see clinical studies 14 6" assertion.
- association label "lucentis is indicated for the treatment of patients with lucentis a vascular endothelial growth factor vegf inhibitor is indicated for the treatment of patients with neovascular wet age related macular degeneration amd 1 1 macular edema following retinal vein occlusion rvo 1 2 diabetic macular edema dme 1 3 diabetic retinopathy dr 1 4 myopic choroidal neovascularization mcnv 1 5" assertion.
- association label "renflexis is a tumor necrosis factor tnf blocker indicated for crohn s disease reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 1 reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease 1 1 pediatric crohn s disease reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 2 ulcerative colitis reducing signs and symptoms inducing and maintaining clinical remission and mucosal healing and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 3 pediatric ulcerative colitis reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 4 rheumatoid arthritis in combination with methotrexate reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active disease 1 5 ankylosing spondylitis reducing signs and symptoms in patients with active disease 1 6 psoriatic arthritis reducing signs and symptoms of active arthritis inhibiting the progression of structural damage and improving physical function 1 7 plaque psoriasis treatment of adult patients with chronic severe i e extensive and or disabling plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate 1 8 renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn s disease who have had an inadequate response to conventional therapy renflexis is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing crohn s disease renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active crohn s disease who have had an inadequate response to conventional therapy renflexis is indicated for reducing signs and symptoms inducing and maintaining clinical remission and mucosal healing and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy renflexis in combination with methotrexate is indicated for reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active rheumatoid arthritis renflexis is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis renflexis is indicated for reducing signs and symptoms of active arthritis inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis renflexis is indicated for the treatment of adult patients with chronic severe i e extensive and or disabling plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate renflexis should only be administered to patients who will be closely monitored and have regular follow up visits with a physician see boxed warnings warnings and precautions 5" assertion.
- association label "renflexis is a tumor necrosis factor tnf blocker indicated for crohn s disease reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 1 reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease 1 1 pediatric crohn s disease reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 2 ulcerative colitis reducing signs and symptoms inducing and maintaining clinical remission and mucosal healing and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 3 pediatric ulcerative colitis reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 4 rheumatoid arthritis in combination with methotrexate reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active disease 1 5 ankylosing spondylitis reducing signs and symptoms in patients with active disease 1 6 psoriatic arthritis reducing signs and symptoms of active arthritis inhibiting the progression of structural damage and improving physical function 1 7 plaque psoriasis treatment of adult patients with chronic severe i e extensive and or disabling plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate 1 8 renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn s disease who have had an inadequate response to conventional therapy renflexis is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing crohn s disease renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active crohn s disease who have had an inadequate response to conventional therapy renflexis is indicated for reducing signs and symptoms inducing and maintaining clinical remission and mucosal healing and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy renflexis in combination with methotrexate is indicated for reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active rheumatoid arthritis renflexis is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis renflexis is indicated for reducing signs and symptoms of active arthritis inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis renflexis is indicated for the treatment of adult patients with chronic severe i e extensive and or disabling plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate renflexis should only be administered to patients who will be closely monitored and have regular follow up visits with a physician see boxed warnings warnings and precautions 5" assertion.
- association label "renflexis is a tumor necrosis factor tnf blocker indicated for crohn s disease reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 1 reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease 1 1 pediatric crohn s disease reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 2 ulcerative colitis reducing signs and symptoms inducing and maintaining clinical remission and mucosal healing and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 3 pediatric ulcerative colitis reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 4 rheumatoid arthritis in combination with methotrexate reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active disease 1 5 ankylosing spondylitis reducing signs and symptoms in patients with active disease 1 6 psoriatic arthritis reducing signs and symptoms of active arthritis inhibiting the progression of structural damage and improving physical function 1 7 plaque psoriasis treatment of adult patients with chronic severe i e extensive and or disabling plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate 1 8 renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn s disease who have had an inadequate response to conventional therapy renflexis is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing crohn s disease renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active crohn s disease who have had an inadequate response to conventional therapy renflexis is indicated for reducing signs and symptoms inducing and maintaining clinical remission and mucosal healing and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy renflexis in combination with methotrexate is indicated for reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active rheumatoid arthritis renflexis is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis renflexis is indicated for reducing signs and symptoms of active arthritis inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis renflexis is indicated for the treatment of adult patients with chronic severe i e extensive and or disabling plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate renflexis should only be administered to patients who will be closely monitored and have regular follow up visits with a physician see boxed warnings warnings and precautions 5" assertion.
- association label "rituxan rituximab is a cd2 directed cytolytic antibody indicated for the treatment of adult patients with non hodgkin s lymphoma nhl 1 1 relapsed or refractory low grade or follicular cd2 positive b cell nhl as a single agent previously untreated follicular cd2 positive b cell nhl in combination with first line chemotherapy and in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy as single agent maintenance therapy non progressing including stable disease low grade cd2 positive b cell nhl as a single agent after first line cyclophosphamide vincristine and prednisone cvp chemotherapy previously untreated diffuse large b cell cd2 positive nhl in combination with cyclophosphamide doxorubicin vincristine and prednisone chop or other anthracycline based chemotherapy regimens chronic lymphocytic leukemia cll 1 2 previously untreated and previously treated cd2 positive cll in combination with fludarabine and cyclophosphamide fc rheumatoid arthritis ra in combination with methotrexate in adult patients with moderately to severely active ra who have inadequate response to one or more tnf antagonist therapies 1 3 granulomatosis with polyangiitis gpa wegener s granulomatosis and microscopic polyangiitis mpa in adult patients in combination with glucocorticoids 1 4 moderate to severe pemphigus vulgaris pv in adult patients 1 5 rituxan rituximab is indicated for the treatment of adult patients with relapsed or refractory low grade or follicular cd2 positive b cell nhl as a single agent previously untreated follicular cd2 positive b cell nhl in combination with first line chemotherapy and in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy as single agent maintenance therapy non progressing including stable disease low grade cd2 positive b cell nhl as a single agent after first line cyclophosphamide vincristine and prednisone cvp chemotherapy previously untreated diffuse large b cell cd2 positive nhl in combination with cyclophosphamide doxorubicin vincristine prednisone chop or other anthracycline based chemotherapy regimens rituxan is indicated in combination with fludarabine and cyclophosphamide fc for the treatment of adult patients with previously untreated and previously treated cd2 positive cll rituxan in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tnf antagonist therapies rituxan in combination with glucocorticoids is indicated for the treatment of adult patients with granulomatosis with polyangiitis gpa wegener s granulomatosis and microscopic polyangiitis mpa rituxan is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris" assertion.
- association label "entyvio is an integrin receptor antagonist indicated for adult ulcerative colitis uc 1 1 adult patients with moderately to severely active uc who have had an inadequate response with lost response to or were intolerant to a tumor necrosis factor tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroids inducing and maintaining clinical response inducing and maintaining clinical remission improving endoscopic appearance of the mucosa achieving corticosteroid free remission adult crohn s disease cd 1 2 adult patients with moderately to severely active cd who have had an inadequate response with lost response to or were intolerant to a tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroids achieving clinical response achieving clinical remission achieving corticosteroid free remission entyvio vedolizumab is indicated for inducing and maintaining clinical response inducing and maintaining clinical remission improving the endoscopic appearance of the mucosa and achieving corticosteroid free remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with lost response to or were intolerant to a tumor necrosis factor tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroids entyvio vedolizumab is indicated for achieving clinical response achieving clinical remission and achieving corticosteroid free remission in adult patients with moderately to severely active crohn s disease who have had an inadequate response with lost response to or were intolerant to a tumor necrosis factor tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroids" assertion.
- association label "levemir is indicated to improve glycemic control in adults and children with diabetes mellitus important limitations of use levemir is not recommended for the treatment of diabetic ketoacidosis intravenous rapid acting or short acting insulin is the preferred treatment for this condition levemir is a long acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus 1 important limitations of use not recommended for treating diabetic ketoacidosis use intravenous rapid acting or short acting insulin instead" assertion.
- association label "odomzo sonidegib is indicated for the treatment of adult patients with locally advanced basal cell carcinoma bcc that has recurred following surgery or radiation therapy or those who are not candidates for surgery or radiation therapy odomzo is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma bcc that has recurred following surgery or radiation therapy or those who are not candidates for surgery or radiation therapy 1" assertion.
- association label "opdivo is a programmed death receptor 1 pd 1 blocking antibody indicated for the treatment of 1 1 1 2 1 3 a 1 4 1 5 1 5 a 1 6 1 7 a 1 8 a 1 9 a 1 1 a opdivo as a single agent or in combination with ipilimumab is indicated for the treatment of patients with unresectable or metastatic melanoma opdivo is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection opdivo is indicated for the treatment of patients with metastatic non small cell lung cancer nsclc with progression on or after platinum based chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fda approved therapy for these aberrations prior to receiving opdivo opdivo is indicated for the treatment of patients with metastatic small cell lung cancer sclc with progression after platinum based chemotherapy and at least one other line of therapy this indication is approved under accelerated approval based on overall response rate and duration of response see clinical studies 14 4 opdivo in combination with ipilimumab is indicated for the treatment of patients with intermediate or poor risk previously untreated advanced rcc opdivo is indicated for the treatment of adult patients with classical hodgkin lymphoma chl that has relapsed or progressed after autologous hematopoietic stem cell transplantation hsct and brentuximab vedotin or 3 or more lines of systemic therapy that includes autologous hsct this indication is approved under accelerated approval based on overall response rate see clinical studies 14 6 opdivo is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck scchn with disease progression on or after platinum based therapy opdivo is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who this indication is approved under accelerated approval based on tumor response rate and duration of response see clinical studies 14 8 opdivo as a single agent or in combination with ipilimumab is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability high msi h or mismatch repair deficient dmmr metastatic colorectal cancer crc that has progressed following treatment with a fluoropyrimidine oxaliplatin and irinotecan this indication is approved under accelerated approval based on overall response rate and duration of response see clinical studies 14 9 opdivo is indicated for the treatment of patients with hepatocellular carcinoma hcc who have been previously treated with sorafenib this indication is approved under accelerated approval based on tumor response rate and durability of response see clinical studies 14 1" assertion.
- association label "apidra is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus apidra is a rapid acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus 1" assertion.
- association label "naglazyme galsulfase is indicated for patients with mucopolysaccharidosis vi mps vi maroteaux lamy syndrome naglazyme has been shown to improve walking and stair climbing capacity naglazyme is a hydrolytic lysosomal glycosaminoglycan gag specific enzyme indicated for patients with mucopolysaccharidosis vi mps vi maroteaux lamy syndrome naglazyme has been shown to improve walking and stair climbing capacity 1" assertion.
- association label "ixinity coagulation factor ix recombinant is a human blood coagulation factor indicated in adults and children 12 years of age with hemophilia b for control and prevention of bleeding episodes perioperative management ixinity is not indicated for induction of immune tolerance in patients with hemophilia b ixinity coagulation factor ix recombinant is a human blood coagulation factor indicated in adults and children 12 years of age with hemophilia b for control and prevention of bleeding episodes perioperative management 1 ixinity is not indicated for induction of immune tolerance in patients with hemophilia b" assertion.
- association label "cyclophosphamide for injection is an alkylating drug indicated for treatment of malignant diseases 1 1 minimal change nephrotic syndrome in pediatric patients 1 2 limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established cyclophosphamide for injection is indicated for the treatment of malignant lymphomas stages iii and iv of the ann arbor staging system hodgkin s disease lymphocytic lymphoma nodular or diffuse mixed cell type lymphoma histiocytic lymphoma burkitt s lymphoma multiple myeloma leukemias chronic lymphocytic leukemia chronic granulocytic leukemia it is usually ineffective in acute blastic crisis acute myelogenous and monocytic leukemia acute lymphoblastic stem cell leukemia cyclophosphamide for injection given during remission is effective in prolonging its duration mycosis fungoides advanced disease neuroblastoma disseminated disease adenocarcinoma of the ovary retinoblastoma carcinoma of the breast cyclophosphamide for injection although effective alone in susceptible malignancies is more frequently used concurrently or sequentially with other antineoplastic drugs cyclophosphamide for injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established" assertion.
- association label "cyclophosphamide for injection is an alkylating drug indicated for treatment of malignant diseases 1 1 minimal change nephrotic syndrome in pediatric patients 1 2 limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established cyclophosphamide for injection is indicated for the treatment of malignant lymphomas stages iii and iv of the ann arbor staging system hodgkin s disease lymphocytic lymphoma nodular or diffuse mixed cell type lymphoma histiocytic lymphoma burkitt s lymphoma multiple myeloma leukemias chronic lymphocytic leukemia chronic granulocytic leukemia it is usually ineffective in acute blastic crisis acute myelogenous and monocytic leukemia acute lymphoblastic stem cell leukemia cyclophosphamide for injection given during remission is effective in prolonging its duration mycosis fungoides advanced disease neuroblastoma disseminated disease adenocarcinoma of the ovary retinoblastoma carcinoma of the breast cyclophosphamide for injection although effective alone in susceptible malignancies is more frequently used concurrently or sequentially with other antineoplastic drugs cyclophosphamide for injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established" assertion.
- association label "noxafil is an azole antifungal agent indicated for injection delayed release tablets and oral suspension prophylaxis of invasive aspergillus candida 1 1 oral suspension treatment of oropharyngeal candidiasis opc including opc refractory ropc to itraconazole and or fluconazole 1 2 noxafil r aspergillus candida noxafil injection is indicated in patients 18 years of age and older noxafil delayed release tablets and oral suspension are indicated in patients 13 years of age and older noxafil oral suspension is indicated for the treatment of oropharyngeal candidiasis including oropharyngeal candidiasis refractory to itraconazole and or fluconazole" assertion.
- association label "enalapril maleate is indicated for the treatment of hypertension enalapril maleate is effective alone or in combination with other antihypertensive agents especially thiazide type diuretics the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive enalapril maleate is indicated for the treatment of symptomatic congestive heart failure usually in combination with diuretics and digitalis in these patients enalapril maleate improves symptoms increases survival and decreases the frequency of hospitalization see clinical pharmacology heart failure mortality trials for details and limitations of survival trials in clinically stable asymptomatic patients with left ventricular dysfunction ejection fraction 35 percent enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure see clinical pharmacology heart failure mortality trials for details and limitations of survival trials in using enalapril maleate consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease and that available data are insufficient to show that enalapril maleate does not have a similar risk see warnings in considering use of enalapril maleate it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in non blacks in addition it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non blacks see warnings head and neck angioedema" assertion.
- association label "ilaris is an interleukin 1b blocker indicated for the treatment of periodic fever syndromes cryopyrin associated periodi c syndromes caps familial cold autoinflammatory syndrome fcas 1 1 muckle wells syndrome mws 1 1 tumor necrosis factor receptor associated periodic syndrome traps 1 1 hyperimmunoglobulin d syndrome hids mevalonate kinase deficiency mkd 1 1 familial mediterranean fever fmf 1 1 active systemic juvenile idiopathic arthritis sjia 1 2 ilaris r cryopyrin associated periodic syndromes caps ilaris is indicated for the treatment of cryopyrin associated periodic syndromes caps in adults and children 4 years of age and older including familial cold autoinflammatory syndrome fcas muckle wells syndrome mws tumor necrosis factor receptor tnf associated periodic syndrome traps ilaris is indicated for the treatment of tumor necrosis factor tnf receptor associated periodic syndrome traps in adult and pediatric patients hyperimmunoglobulin d syndrome hids mevalonate kinase deficiency mkd ilaris is indicated for the treatment of hyperimmunoglobulin d hyper igd syndrome hids mevalonate kinase deficiency mkd in adult and pediatric patients familial mediterranean fever fmf ilaris is indicated for the treatment of familial mediterranean fever fmf in adult and pediatric patients ilaris is indicated for the treatment of active systemic juvenile idiopathic arthritis sjia in patients aged 2 years and older" assertion.
- patient_undergoing_PCI label "patient undergoing PCI" assertion.
- cost-effective_treatment label "cost-effective treatment" assertion.
- association label "this association" assertion.
- readableassertion label "describe the assertion concisely (e.g. tylenol treats pain in adults patients)" assertion.
- subject label "search for the indicated drug" assertion.
- cohortAgeLabel label "describe the life stage or age of the cohort (e.g. Adults)" assertion.
- cohortAgeMax label "describe the maximum age of the cohort (e.g. 80)" assertion.
- objectNarrower label "optionally provide a narrower concepts for the disease" assertion.
- publication label "add the URL of a publication supporting this association (doi, PubMed...)" assertion.
- associationRelation label "provide the type of drug indication" assertion.
- object label "search for the disease it treats" assertion.
- cohortAgeMin label "describe the minimum age of the cohort (e.g. 7)" assertion.
- cohort label "the study cohort" assertion.
- hasPhenotype label "provide additional phenotypes for the cohort" assertion.
- assertion label "Defining a drug indication with its context (BioLink model)" assertion.
- narrow_match label "has more specific concept" assertion.
- narrow_match label "narrow match - a list of terms from different schemas or terminology systems that have a narrower, more specific meaning. Narrower terms are typically shown as children in a hierarchy or tree." assertion.
- narrow_match label "narrow match - a list of terms from different schemas or terminology systems that have a narrower, more specific meaning. Narrower terms are typically shown as children in a hierarchy or tree." assertion.
- openbiodiv-knowledge-graph label "OpenBiodiv knowledge graph" assertion.
- semantic-triples-extracted-from-biodiversity-literature label "semantic triple extracted from biodiversity literature" assertion.
- biodiversity-data-reuse label "biodiversity data reuse" assertion.
- spi label "The OpenBiodiv knowledge graph contains semantic triples extracted from biodiversity literature" assertion.
- obesity-wih-metabolic-abnormality label "obesity with metabolic abnormality" assertion.
- obesity-wih-metabolic-abnormality label "obesity wih metabolic abnormality" assertion.
- object label "search for the disease it treats" assertion.
- readableassertion label "describe the assertion concisely (e.g. tylenol treats pain in adults patients)" assertion.
- cohortAgeMax label "describe the maximum age of the cohort (e.g. 80)" assertion.
- cohort label "the study cohort" assertion.
- subject label "search for the indicated drug" assertion.
- association label "this association" assertion.
- hasPhenotype label "provide additional phenotypes for the cohort" assertion.
- cohortAgeLabel label "describe the life stage or age of the cohort (e.g. Adults)" assertion.
- publication label "add the URL of a publication supporting this association (doi, PubMed...)" assertion.
- cohortAgeMin label "describe the minimum age of the cohort (e.g. 7)" assertion.
- associationRelation label "provide the type of drug indication" assertion.
- assertion label "Defining a drug indication with its context (BioLink model)" assertion.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.